Key Drivers
- Strong cash flow
- High leverage
- Low asset efficiency
AIAI Summary
GRFS is now less about proving the business works and more about proving that FESILTY, the Phase 3 immunoglobulin programs, and SPARTA can convert clinical progress into faster free cash flow and eventual deleveraging, because with about $8.8B net debt and only ~1.8x interest coverage the stock will rerate only if operating gains outrun balance-sheet risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash flow
- •High leverage
- •Low asset efficiency
GRFS shows solid revenue, margins, cash flow, and a reasonable valuation, but high leverage, thin interest coverage, and weak asset efficiency keep the risk profile mixed.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •8.00 reclaim
- •Momentum fade
GRFS is modestly up over the last month, but the recent drop from $8.05 to $7.78 shows fading momentum and a need to reclaim $8.00 to strengthen the bullish case.
Recent slide from $8.05 to $7.78 signals cooling near-term control
Sentiment & News
Key News Insights:
- •Immunoglobulin growth
- •Phase 3 expansion
- •SPARTA completion
Grifols is steadily advancing its core immunoglobulin and alpha-1 programs, with Q2 progress, new Phase 3 dosing, and completion of the SPARTA study supporting its 2026 targets.
Positive, as the updates reinforce execution and lower clinical uncertainty around Grifols' core portfolio
Similar Companies in Healthcare
Other companies in the same sector with AI ratings